Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor.
Left ventricular function and neurohormonal status in patients with heart failure remaining symptomatic during therapy with angiotensin-converting enzyme inhibitors were assessed, and the effects of dopaminergic receptor stimulation in this setting were determined. Neurohormonal and left ventricular function (radionuclide angiography) data were obtained in 19 patients with symptomatic ischemic heart failure. Measurements were repeated after 4 to 6 weeks of therapy with the dopamine agonist ibopamine (100 mg, 3 times/day) or placebo administered in a double-blind, randomized, parallel group design. At baseline, despite therapy with enalapril, the angiotensin II levels (mean 39.4 pg/ml; p < 0.01 vs controls) were significantly increased, as were plasma norepinephrine (497 +/- 240 pg/ml; p < 0.01 vs controls), endothelin-1, atrial natriuretic peptide and arginine vasopressin. Moreover, in comparison with pretreatment values, left ventricular ejection fraction had decreased substantially (-9.1%) in patients with plasma norepinephrine > or = 600 pg/ml, but not in those with lower values of norepinephrine. With ibopamine, plasma norepinephrine decreased from 516 +/- 241 to 391 +/- 208 pg/ml (n = 8; p < 0.025 vs placebo), whereas it increased with placebo. In conclusion, the neurohormonal control provided by an angiotensin-converting enzyme inhibitor is reduced in a large subset of patients during prolonged therapy; ibopamine appears to be a potentially useful drug to improve neurohormonal control in this setting.
Rousseau
M F
MF
Division of Cardiology and Endocrinology, University of Louvain, School of Medicine, Brussels, Belgium.
Konstam
M A
MA
Benedict
C R
CR
Donckier
J
J
Galanti
L
L
Melin
J
J
Kinan
D
D
Ahn
S
S
Ketelslegers
J M
JM
Pouleur
H
H
D000368:Aged; D003327:Coronary Disease / Q000097:blood / Q000150:complications* / Q000503:physiopathology; D003846:Deoxyepinephrine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015259:Dopamine Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D015536:Down-Regulation; D004359:Drug Therapy, Combination; D004656:Enalapril / Q000627:therapeutic use*; D005260:Female; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000097:blood*; D011954:Receptors, Dopamine / Q000187:drug effects; D016277:Ventricular Function, Left / Q000187:drug effects*
D015259:Dopamine Agents; D011954:Receptors, Dopamine; D004656:Enalapril; C023487:ibopamine; D003846:Deoxyepinephrine; D009638:Norepinephrine